genexishub.com

1. The core of pharmacology and biotechnology business model is the complex process of drug development. Various challenges include expiry of blockbuster patents, competition from generics and biosimilars, shift towards personalised medicines, and also the pressure on pricing have led to pharmaceutical companies to enhance their efforts in the hunt for new and smarter approaches to drugs- and diagnostics development. Today, companies are frequently putting comprehensive index of contract biotech service providers outsourcing strategies in place to speed up the overall process and to increase the efficiency of drug development. Furthermore, pharma and biotechnology companies are reshaping the drug development services industry by building new partnerships for their research and development. Germany − the top pharma market in Europe and the number four worldwide − is also a heavyweight in medical biotechnology. The picture today is of a vital and highly diversified contract research landscape, covering all the stages in drug development and value creation. The range of advanced high technologies on offer and an excellent biomedical research and clinical infrastructure makes the German market truly unique. A contract research organisation is a service organisation or company that provides support in the form of research services to the pharmaceutical and biotechnology industries. These are typically outsourced on a contract basis, and can take in services such as target validation, lead optimisation including delivery technologies, ADMET studies, bioanalytics, and clinical trials management. This approach sees an active role for a range of contract research providers along the complete value chain in drug discovery and development.